Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Cereno Scientific

6.70 SEK

+1.98 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.98 %
-0.67 %
-4.15 %
+2.68 %
-27.84 %
+34.11 %
+235.00 %
+262.16 %
+11.46 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
2.09B SEK
Turnover
2.67M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/2
2026

Annual report '25

29/4
2026

Interim report Q1'26

17/6
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Third party researchyesterday

Cereno Scientific: CMD reaffirms shifting focus to clinical delivery - Edison

Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by key opinion leader (KOL) and patient perspectives, ...

Cereno Scientific
Press release2/5/2026, 11:45 AM

Investor Studios: Cereno Scientifics kapitalmarknadsdag sänds live klockan 13.00

Cereno Scientific
Press release2/4/2026, 9:00 AM

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/4/2026, 9:00 AM

Cereno Scientific breddar utvecklingsfokus för CS014 till pulmonell hypertension associerad med interstitiell lungsjukdom

Cereno Scientific
Press release2/3/2026, 6:45 AM

Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026

Cereno Scientific
Press release2/3/2026, 6:45 AM

Cereno Scientific lämnar uppdatering om Expanded Access Program för CS1 - initiala insikter förväntas under Q1 2026

Cereno Scientific
Press release2/2/2026, 1:00 PM

Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific
Press release2/2/2026, 1:00 PM

Cereno Scientific presenterar program och talare för kapitalmarknadsdagen den 5 februari

Cereno Scientific
Press release1/28/2026, 12:02 PM

Cereno Scientific presenterar CS014-data och deltar i paneldiskussion vid den vetenskapliga konferensen PVRI 2026 i Dublin

Cereno Scientific
Press release1/28/2026, 12:02 PM

Cereno Scientific to Present CS014 Data and Participate in Panel at Scientific Conference PVRI 2026 Dublin

Cereno Scientific
Press release1/16/2026, 6:45 AM

Cereno Scientific: Invitation to Capital Markets Day 2026

Cereno Scientific
Press release1/16/2026, 6:45 AM

Cereno Scientific: Inbjudan till kapitalmarknadsdag den 5 februari 2026

Cereno Scientific
Press release1/14/2026, 12:15 PM

Cereno Scientific delar första vetenskapliga publikationen om HDAC-hämmaren CS014: Antitrombotisk effekt utan blödningsrisk stödjer bred potential vid kardiopulmonella sjukdomar

Cereno Scientific
Press release1/14/2026, 12:15 PM

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases

Cereno Scientific
Third party research1/13/2026, 6:18 AM

Cereno Scientific: Entering a value inflection phase - Edison

We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II development of CS014 shortly thereafter. With the FDA...

Cereno Scientific
Regulatory press release1/8/2026, 9:45 AM

Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP

Cereno Scientific
Regulatory press release1/8/2026, 9:45 AM

Cereno Scientific erhåller cirka 5 miljoner kronor genom utnyttjande av 728 957 teckningsoptioner av Arena Investors, LP

Cereno Scientific
Press release12/18/2025, 1:50 PM

Cereno Scientifics styrelse och ledning ingår lock-up avtal

Cereno Scientific
Press release12/18/2025, 1:50 PM

Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements

Cereno Scientific
Press release12/18/2025, 9:00 AM

Cereno Scientific anordnar kapitalmarknadsdag den 5 februari 2026

Cereno Scientific
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.